| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $11,017,005 ) (Continued on the next page) |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | NU52PS910245 | TB Centers of Excellence for Training, Education and Medical Consultation (TB COE) | 00 | 4 | CDC | 1/5/2026 | $3,750 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA285439 | Preclinical and clinical characterization of DNMT inhibitors +/- standard chemoimmunotherapy in TNBC | 000 | 2 | NIH | 12/10/2025 | $417,118 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA269384 | Re-purposing Oncolytic Virotherapy to Re-invigorate CAR T Cell Therapy for Solid Tumors. | 000 | 4 | NIH | 12/9/2025 | $327,341 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AG076636 | Advancing MR elastography to map mechanical signatures of key AD/ADRD processes | 000 | 4 | NIH | 11/26/2025 | $397,775 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AG081955 | Validation of the Mayo Test Drive Screening Battery Composite and Stricker Learning Span for Early Detection and Monitoring of Cognitive Decline in Preclinical and Prodromal Alzheimer’s Disease | 000 | 3 | NIH | 12/1/2025 | $1,347,320 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AI162678 | Context dependent amino acid availability and sensing determines humoral immunity | 000 | 5 | NIH | 1/9/2026 | $470,828 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AR076347 | The Role of Cellular Senescence in Carpal Tunnel Syndrome | 000 | 6 | NIH | 12/5/2025 | $603,632 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA132878 | Post-translational Modifications in DNA Damage Response: a Structural Perspective | 000 | 13 | NIH | 12/30/2025 | $363,150 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | K99AG090620 | T cell surveillance of senescent cells under homeostasis and aging | 001 | 2 | NIH | 1/9/2026 | $0 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | K99AG090620 | T cell surveillance of senescent cells under homeostasis and aging | 000 | 2 | NIH | 12/10/2025 | $133,353 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | K01DK141911 | Mechanisms of Resistance Exercise Training for Improved Muscle Insulin Sensitivity | 000 | 2 | NIH | 12/22/2025 | $142,374 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | F30HD115297 | Role of Hofbauer cells in prenatal inflammation at the maternal-fetal interface | 000 | 2 | NIH | 12/24/2025 | $49,738 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R37CA266344 | Towards Safer and More Effective CART Cell Therapy Through the Modulation of Myeloid Cytokines | 000 | 5 | NIH | 12/5/2025 | $554,542 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R21AI188334 | Discovery of efflux pump inhibitors using a high-throughout bacterial assay | 001 | 2 | NIH | 12/29/2025 | $201,750 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R21CA288898 | Evaluating Maintenance In Light chain Amyloidosis (EMILIA) | 000 | 2 | NIH | 12/17/2025 | $169,826 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R21CA277138 | Novel 3D DWI for Detection and Characterization of Prostate Cancer in Men with Pelvic Metal Implants | 000 | 3 | NIH | 12/11/2025 | $203,727 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01NS076491 | Computational and Biological Approach to Flow Diversion | 000 | 15 | NIH | 12/10/2025 | $405,317 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01MH131623 | Uncovering the origin of hypermutability in adult brains | 000 | 3 | NIH | 12/10/2025 | $844,959 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01GM144351 | Methods for microbiome compositional data | 000 | 5 | NIH | 1/15/2026 | $295,088 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01DK099160 | Molecular dissection of the ciliary gate | 000 | 12 | NIH | 12/15/2025 | $424,643 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01DK090358 | Automated detection of microstructural features that have unique protein markers and are prognostic for chronic kidney disease | 000 | 15 | NIH | 1/12/2026 | $687,548 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01DK117861 | Molecular Mechanisms of Cholestatic Fibrogenesis | 000 | 8 | NIH | 12/30/2025 | $351,045 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01DK133401 | Heme-mediated Mitochondrial Injury, Senescence, Acute Kidney Injury and Chronic Kidney Disease | 000 | 4 | NIH | 1/12/2026 | $599,173 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01DK134448 | NAFLD Diagnosis and Outcomes | 000 | 3 | NIH | 1/14/2026 | $530,351 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01DK130854 | Role of SLCO3A1 in macrophage metabolite sensing and IBD | 000 | 4 | NIH | 1/14/2026 | $349,800 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01DK129240 | Role of mitochondrial microRNAs (mitomiRs) in endogenous renal repair | 000 | 4 | NIH | 12/19/2025 | $454,996 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01DK129205 | Renal Microvessel Imaging for Characterization of Chronic Kidney Disease | 000 | 4 | NIH | 12/18/2025 | $530,101 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01EB033008 | Development of an ultrasound detectable, migration-resistant biopsy marker for improving care in patients with breast cancer | 000 | 4 | NIH | 1/7/2026 | $487,266 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01EB017095 | Diagnostic performance assessment and dose optimization using patient CT images: Application to deep-learning CT reconstruction and denoising technologies | 000 | 12 | NIH | 1/7/2026 | $421,277 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01DK139607 | Investigate the trafficking and function of polycystins in primary cilia and their implications for polycystic kidney disease | 000 | 3 | NIH | 1/9/2026 | $541,708 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA288753 | Ovcoming PARP Inhibitor Resistance | 000 | 2 | NIH | 12/10/2025 | $570,333 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA275870 | Investigating the role of MAP2 in chemotherapy-induced peripheral neurotoxicity | 000 | 4 | NIH | 12/23/2025 | $559,858 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA273027 | Role of MALT1 in regulating the breast cancer immune microenvironment | 000 | 4 | NIH | 12/5/2025 | $489,319 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA271503 | Synthetic Lethal Targeting of SETD2 in Renal Cell Carcinoma | 000 | 4 | NIH | 12/22/2025 | $485,587 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA288862 | NT-I7, a novel long-acting interleukin-7, in combination with anti-PD-1 checkpoint blockade for the treatment of glioablastoma | 000 | 2 | NIH | 1/13/2026 | $582,338 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | NU52PS910245 | TB Centers of Excellence for Training, Education and Medical Consultation (TB COE) | 00 | 4 | CDC | 1/5/2026 | $652,176 |
| | 2026 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AG071686 | Systemic Cell Senescence as a Mediator of Brain Aging Through Circulation | 000 | 5 | NIH | 12/3/2025 | $0 |
| | 2026 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AI108889 | Mechanisms of allostery and molecular recognition in efflux pumps | 001 | 12 | NIH | 1/15/2026 | $507,975 |
| | 2026 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | K99HL171911 | The role of proteoglycans in Heparin-induced thrombocytopenia: Implications for pathophysiology, diagnosis and treatment | 000 | 2 | NIH | 12/12/2025 | $0 |
| | 2026 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | P30CA015083 | Mayo Clinic Comprehensive Cancer Center Support Grant | 000 | 50 | NIH | 12/2/2025 | $0 |
| | 2026 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AA029258 | Astrocyte-Neuron Interaction in the Dorsal Striatum and Ethanol-Seeking Behaviors | 000 | 5 | NIH | 1/7/2026 | $0 |
| | 2026 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AG065154 | Beta1-selective blockade for prevention of postmenopausal bone loss: A randomized controlled trial | 000 | 5 | NIH | 11/14/2025 | $0 |
| | 2026 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | P50CA210964 | Mayo Clinic Hepatobiliary SPORE | 000 | 7 | NIH | 12/4/2025 | $0 |
| | 2026 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | K23MD016230 | Rural Patient Risks and Exposures for Diabetes ConTrol (Rural PREDICT) | 000 | 5 | NIH | 1/7/2026 | $0 |
| | 2026 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | K08CA252178 | DNA Damage and Immunogenicity in Ewing Sarcoma | 001 | 6 | NIH | 1/9/2026 | $87,882 |
| | 2026 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | U24CA274496 | Management and Data Coordination Unit for PCDC | 000 | 4 | NIH | 12/18/2025 | $0 |
| | 2026 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | U24DK112326 | Mayo Clinic Physical Activity Research Center: Metabolomics and Proteomics Analysis Site | 001 | 8 | NIH | 1/6/2026 | $0 |
| | 2026 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | U01CA271410 | Mayo Clinic Center for Clinical Proteomics | 000 | 4 | NIH | 11/24/2025 | $0 |
| | 2026 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R34MH128296 | Evaluating the feasibility of a primary care-based treatment for restrictive eating disorders in children and adolescents | 000 | 3 | NIH | 11/21/2025 | $0 |
|
